Additionally, the study showed that the high expressions of CCL3, CCL4 and CXCL10, independent of sex, age, FAB phenotype, patient status and risk molecular, were associated with the poor outcome of AML patients, suggesting they are valuable for AML prognosis. Here, CCL3 is linked to acute myeloid leukemia.